Alemtuzumab: Difference between revisions
CSV import |
CSV import |
||
| Line 41: | Line 41: | ||
[[Category:Multiple sclerosis treatments]] | [[Category:Multiple sclerosis treatments]] | ||
[[Category:Leukemia treatments]] | [[Category:Leukemia treatments]] | ||
== Alemtuzumab == | |||
<gallery> | |||
File:Alemtuzumab Fab 1CE1.png|Alemtuzumab | |||
</gallery> | |||
== Alemtuzumab == | == Alemtuzumab == | ||
<gallery> | <gallery> | ||
File:Alemtuzumab Fab 1CE1.png|Alemtuzumab | File:Alemtuzumab Fab 1CE1.png|Alemtuzumab | ||
</gallery> | </gallery> | ||
Latest revision as of 00:55, 20 February 2025
A monoclonal antibody used in the treatment of multiple sclerosis and certain types of leukemia
| Alemtuzumab | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Alemtuzumab is a monoclonal antibody used in the treatment of multiple sclerosis and certain types of leukemia, such as chronic lymphocytic leukemia (CLL). It targets the CD52 antigen, a protein present on the surface of mature lymphocytes.
Mechanism of Action[edit]
Alemtuzumab works by binding to the CD52 antigen on the surface of B cells and T cells. This binding triggers the destruction of these cells by the immune system, primarily through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). By depleting these lymphocytes, alemtuzumab modulates the immune system, which is beneficial in conditions like multiple sclerosis and leukemia.
Medical Uses[edit]
Alemtuzumab is primarily used in the treatment of:
- Multiple sclerosis: It is used to reduce the frequency of relapses and delay the progression of disability in patients with relapsing forms of the disease.
- Chronic lymphocytic leukemia (CLL): It is used in patients who have been treated with other therapies without success.
Administration[edit]
Alemtuzumab is administered via intravenous infusion. The dosing regimen varies depending on the condition being treated. For multiple sclerosis, it is typically given in two courses, with the first course consisting of daily infusions for five consecutive days, and the second course given a year later for three consecutive days.
Side Effects[edit]
Common side effects of alemtuzumab include:
- Infusion reactions such as rash, headache, and fever
- Increased risk of infections due to immunosuppression
- Autoimmune conditions, such as thyroid disorders and immune thrombocytopenic purpura (ITP)
History[edit]
Alemtuzumab was originally developed as a treatment for leukemia. It was later found to be effective in treating multiple sclerosis, leading to its approval for this indication. The drug was initially marketed under the brand name Campath for leukemia and later as Lemtrada for multiple sclerosis.
Related pages[edit]
Alemtuzumab[edit]
-
Alemtuzumab
Alemtuzumab[edit]
-
Alemtuzumab
